Compare Noble Corporation plc (NE) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs State Street SPDR S&P Biotech ETF — how do they compare? Noble Corporation plc trades at $42.35 (market cap $6.73B), while State Street SPDR S&P Biotech ETF trades at $151.86 (market cap $10.11B). The key difference: State Street SPDR S&P Biotech ETF is the larger of the two by market cap, and Noble Corporation plc pays a 4.74% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 26 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| NE | XBI | |
|---|---|---|
Market Cap | $6.73B | $10.11B |
Volume | 1,027,635 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $54.37 | $169.55 |
52-Week Low | $26.70 | $104.99 |
Typical Hold Time | 26 Days | 37 Days |
Enterprise Value | $8.16B | — |
Dividend Yield | 4.74% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $42.21, up 3.03% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported declining revenue from $3.29B in 2025 to $3.1B in 2026, with net income dropping from $217M to $150M. Recent positive developments include securing a long-term drilling contract in Ghana, though earnings have been inconsistent with two misses and one beat in the last four quarters.
The stock presents a cautious opportunity with analyst consensus target of $52.00 offering 23% upside, but faces headwinds from declining profitability and ongoing SEC investigation. Investors should weigh the contract wins against execution risks and margin pressure in the offshore drilling sector.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
